Charles River Laboratories has launched its off-the-shelf lentiviral vector (LVV) packaging plasmids, with the aim of providing a streamlined solution to the challenges associated with plasmid sourcing in cell and gene therapies.   Cell and gene therapies often rely on plasmid DNA (pDNA) as a critical starting material. However, production challenges such as capacity bottlenecks and timeline pressures, as well as a need for process development optimization can result in increased lead time, co...